ArticleBMC cancer2026
Comparative study of clinical features, pathology, and immunophenotype between HIV-related cutaneous and visceral Kaposi's sarcoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundKaposi’s sarcoma (KS) remains a significant challenge in HIV-infected individuals, with visceral KS posing a greater therapeutic dilemma due to its aggressive nature compared to the cutaneous form. The differential immune microenvironment and molecular pathology underlying this clinical disparity are poorly understood. This study aimed to compare the clinicopathological and immunophenotypic characteristics between HIV-related cutaneous and visceral KS, with a focus on the PD-1/PD-L1 pathway, key regulatory molecules, and their association with HHV8 status.
methodsClinical data from 21 patients with cutaneous KS and 14 patients with visceral KS were collected. Their clinical features, serum CD3/CD4/CD8 levels, histopathology, and immunohistochemical marker expression were analyzed and compared, and disease-free survival (DFS) was evaluated.
resultsThe incidence of HIV infection duration ≤ 1 month was significantly higher in cutaneous KS than in visceral KS (P < 0.05). The mean peripheral blood CD3, CD4, and CD8 levels were higher in the cutaneous group. Immunohistochemical analysis revealed that cyclinD1, Rb, P53, HHV8, PD-1, PD-L1, and Ki-67 were more highly expressed in visceral KS than in cutaneous KS, with statistically significant differences in P53 and BCL-2 expression (P < 0.05). In the HHV8 high-expression subgroup, PD-1 and PD-L1 levels were significantly higher in visceral KS than in cutaneous KS (P < 0.05). Conversely, in the HHV8 low-expression subgroup, PD-1 and PD-L1 levels were significantly higher in cutaneous KS than in visceral KS (P < 0.05).
conclusion(1) Distinct molecular profiles in the PD-1/PD-L1 pathway, cell cycle (CyclinD1/Rb), and apoptosis regulation (P53/BCL-2) differentiate cutaneous from visceral KS, underscoring their divergent aggressiveness; (2) PD-1/PD-L1 expression is critically dependent on HHV8 viral load, exhibiting opposing patterns across anatomical sites, which highlights the complex immune interplay in KS and underscores the aggressive nature of visceral disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.